{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T02:09:53Z","timestamp":1778206193044,"version":"3.51.4"},"reference-count":33,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.jacadv.2025.102419","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T19:05:24Z","timestamp":1769627124000},"page":"102419","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Empagliflozin in Heart Failure and Previous Coronary Revascularization"],"prefix":"10.1016","volume":"5","author":[{"given":"Nitish K.","family":"Dhingra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan D.","family":"Anker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joao Pedro","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Egon","family":"Pfarr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5088-4164","authenticated-orcid":false,"given":"Tomasz","family":"Gasior","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matias","family":"Nordaby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Brueckmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart J.","family":"Pocock","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7456-1570","authenticated-orcid":false,"given":"Faiez","family":"Zannad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Milton","family":"Packer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4018-8533","authenticated-orcid":false,"given":"Subodh","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jacadv.2025.102419_bib1","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.003875","article-title":"Significance of ischemic heart disease in patients with heart failure and preserved, midrange, and reduced ejection fraction: a nationwide cohort study","volume":"10","author":"Vedin","year":"2017","journal-title":"Circ Heart Fail"},{"issue":"2","key":"10.1016\/j.jacadv.2025.102419_bib2","doi-asserted-by":"crossref","first-page":"e21","DOI":"10.1016\/j.jacc.2021.09.006","article-title":"2021 ACC\/AHA\/SCAI guideline for coronary artery revascularization: a report of the American college of cardiology\/American Heart Association Joint Committee on clinical practice guidelines","volume":"79","author":"Lawton","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.jacadv.2025.102419_bib3","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.mayocpiqo.2021.09.001","article-title":"Modifiable risk factors and residual risk following coronary revascularization: insights from a regionalized dedicated follow-up clinic","volume":"5","author":"Simard","year":"2021","journal-title":"Mayo Clin Proc Innov Qual Outcomes"},{"issue":"15","key":"10.1016\/j.jacadv.2025.102419_bib4","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.jacadv.2025.102419_bib5","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jacadv.2025.102419_bib6","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1093\/eurheartj\/ehab798","article-title":"Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction","volume":"43","author":"Butler","year":"2022","journal-title":"Eur Heart J"},{"issue":"16","key":"10.1016\/j.jacadv.2025.102419_bib7","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1056\/NEJMoa2314051","article-title":"Empagliflozin after acute myocardial infarction","volume":"390","author":"Butler","year":"2024","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.jacadv.2025.102419_bib8","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1002\/ejhf.2990","article-title":"Baseline characteristics of patients enrolled in the EMPACT-MI trial","volume":"25","author":"Harrington","year":"2023","journal-title":"Eur J Heart Fail"},{"issue":"21","key":"10.1016\/j.jacadv.2025.102419_bib9","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1161\/CIRCULATIONAHA.124.069217","article-title":"Effect of empagliflozin on heart failure outcomes after acute myocardial infarction: insights from the EMPACT-MI trial","volume":"149","author":"Hernandez","year":"2024","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.jacadv.2025.102419_bib10","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1002\/ejhf.1536","article-title":"Evaluation of the effect of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-reduced trial","volume":"21","author":"Packer","year":"2019","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"10.1016\/j.jacadv.2025.102419_bib11","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1002\/ejhf.1596","article-title":"Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-preserved trial","volume":"21","author":"Anker","year":"2019","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"10.1016\/j.jacadv.2025.102419_bib12","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1002\/ejhf.2065","article-title":"Design of a prospective patient-level pooled analysis of two parallel trials of empagliflozin in patients with established heart failure","volume":"22","author":"Packer","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"16","key":"10.1016\/j.jacadv.2025.102419_bib13","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1056\/NEJMoa1602001","article-title":"Coronary-artery bypass surgery in patients with ischemic cardiomyopathy","volume":"374","author":"Velazquez","year":"2016","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.jacadv.2025.102419_bib14","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1056\/NEJMoa2206606","article-title":"Percutaneous revascularization for ischemic left ventricular dysfunction","volume":"387","author":"Perera","year":"2022","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.jacadv.2025.102419_bib15","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa1915922","article-title":"Initial invasive or conservative strategy for stable coronary disease","volume":"382","author":"Maron","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jacadv.2025.102419_bib16","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1161\/CIRCULATIONAHA.119.044235","article-title":"Effect of empagliflozin on erythropoietin levels, iron stores, and red blood cell morphology in patients with type 2 diabetes mellitus and coronary artery disease","volume":"141","author":"Mazer","year":"2020","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.jacadv.2025.102419_bib17","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1161\/CIRCULATIONAHA.119.042375","article-title":"Effect of empagliflozin on left ventricular mass in patients with type 2 diabetes mellitus and coronary artery disease: the EMPA-HEART CardioLink-6 randomized clinical trial","volume":"140","author":"Verma","year":"2019","journal-title":"Circulation"},{"issue":"48","key":"10.1016\/j.jacadv.2025.102419_bib18","doi-asserted-by":"crossref","first-page":"4991","DOI":"10.1093\/eurheartj\/ehac495","article-title":"Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme","volume":"43","author":"Zannad","year":"2022","journal-title":"Eur Heart J"},{"issue":"6","key":"10.1016\/j.jacadv.2025.102419_bib19","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.jacbts.2020.02.004","article-title":"Mechanisms of cardiovascular benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors: a state-of-the-art review","volume":"5","author":"Lopaschuk","year":"2020","journal-title":"JACC Basic Transl Sci"},{"issue":"16","key":"10.1016\/j.jacadv.2025.102419_bib20","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.016270","article-title":"Molecular, cellular, and clinical evidence that sodium-glucose cotransporter 2 inhibitors act as neurohormonal antagonists when used for the treatment of chronic heart failure","volume":"9","author":"Packer","year":"2020","journal-title":"J Am Heart Assoc"},{"issue":"3","key":"10.1016\/j.jacadv.2025.102419_bib21","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2337\/dci19-0074","article-title":"SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding their mechanism of action","volume":"43","author":"Packer","year":"2020","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.jacadv.2025.102419_bib22","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/ejhf.1732","article-title":"Autophagy stimulation and intracellular sodium reduction as mediators of the cardioprotective effect of sodium-glucose cotransporter 2 inhibitors","volume":"22","author":"Packer","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.jacadv.2025.102419_bib23","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.119.006277","article-title":"Empagliflozin blunts worsening cardiac dysfunction associated with reduced NLRP3 (nucleotide-binding domain-like receptor protein 3) inflammasome activation in heart failure","volume":"13","author":"Byrne","year":"2020","journal-title":"Circ Heart Fail"},{"issue":"18","key":"10.1016\/j.jacadv.2025.102419_bib24","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1161\/CIRCULATIONAHA.122.061732","article-title":"Critical reanalysis of the mechanisms underlying the cardiorenal benefits of SGLT2 inhibitors and reaffirmation of the nutrient deprivation signaling\/autophagy hypothesis","volume":"146","author":"Packer","year":"2022","journal-title":"Circulation"},{"issue":"11","key":"10.1016\/j.jacadv.2025.102419_bib25","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1161\/CIRCULATIONAHA.120.045691","article-title":"Empagliflozin in heart failure: diuretic and cardiorenal effects","volume":"142","author":"Griffin","year":"2020","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.jacadv.2025.102419_bib26","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1016\/j.cardfail.2021.07.003","article-title":"The potential roles of osmotic and nonosmotic sodium handling in mediating the effects of sodium-glucose cotransporter 2 inhibitors on heart failure","volume":"27","author":"Bjornstad","year":"2021","journal-title":"J Card Fail"},{"issue":"7","key":"10.1016\/j.jacadv.2025.102419_bib27","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1007\/s00380-020-01768-w","article-title":"Glucose-dependent diuresis in relation to improvements in renal-tubular markers of sodium-glucose cotransporter-2 inhibitors in hospitalized heart failure patients with diabetes","volume":"36","author":"Ikeda","year":"2021","journal-title":"Heart Vessels"},{"key":"10.1016\/j.jacadv.2025.102419_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.vph.2021.106839","article-title":"Exploring the mechanisms of action of gliflozines in heart failure and possible implications in pulmonary hypertension","volume":"138","author":"Madonna","year":"2021","journal-title":"Vascul Pharmacol"},{"issue":"18","key":"10.1016\/j.jacadv.2025.102419_bib29","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1161\/CIRCULATIONAHA.120.048739","article-title":"Renal and cardiovascular effects of SGLT2 inhibition in combination with loop diuretics in patients with type 2 diabetes and chronic heart failure: the RECEDE-CHF trial","volume":"142","author":"Mordi","year":"2020","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.jacadv.2025.102419_bib30","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/ejhf.1713","article-title":"Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF)","volume":"22","author":"Damman","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10.1016\/j.jacadv.2025.102419_bib31","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/jcph.1987","article-title":"Predicted cardiac functional responses to renal actions of SGLT2i in the DAPACARD trial population: a mathematical modeling analysis","volume":"62","author":"Yu","year":"2022","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.jacadv.2025.102419_bib32","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/jcph.1769","article-title":"Predicted cardiac hemodynamic consequences of the renal actions of SGLT2i in the DAPA-HF study population: a mathematical modeling analysis","volume":"61","author":"Yu","year":"2021","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.jacadv.2025.102419_bib33","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.027652","article-title":"Impact of empagliflozin in heart failure with reduced ejection fraction in patients with ischemic versus nonischemic cause","volume":"12","author":"Khan","year":"2023","journal-title":"J Am Heart Assoc"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X25008488?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X25008488?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T01:14:55Z","timestamp":1778202895000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X25008488"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S2772963X25008488"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2025.102419","relation":{},"ISSN":["2772-963X"],"issn-type":[{"value":"2772-963X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Empagliflozin in Heart Failure and Previous Coronary Revascularization","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2025.102419","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"102419"}}